Multiple biomarkers from various locations within the tumor may play a role in the angiogenesis, because as early as 2012, Lambrechts et al. uncovered the genetic variant’s role in determining the VEGF circulation level [106], performing a very comprehensive SNPs analysis for all the anti-angiogenic factors, uncovering rs7993418 inVEGFR-1 to have a predictive value in bevacizumab response in pancreatic cancer patients enrolled in the AviTA study, with an improved survival. This evidence concerns the gene VEGFA and pancreatic neoplasm.